Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | ADH1B | P00325 | 3/20 | 0.42 |
| ▸ | ADH1A | P07327 | 3/20 | 0.42 |
| ▸ | ADH7 | P40394 | 3/20 | 0.42 |
| ▸ | ADH1C | P00326 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | ADH4 | P08319 | 1/20 | 0.41 |
| ▸ | SPR | P35270 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CASP2 | P42575 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8326097 | 0.86 | TSHR (0.54) | TSHRFAAHMEN1KMT2AEPHX1 | |
| SCHEMBL8537389 | 0.84 | FAAH (0.55) | TSHRFAAHMEN1KMT2AEPHX1 | |
| SCHEMBL7786356 | 0.84 | FAAH (0.55) | TSHRFAAHMEN1KMT2AEPHX1 | |
| SCHEMBL10311847 | 0.83 | TSHR (0.44) | TSHRFAAHMEN1KMT2ASPR | |
| SCHEMBL22837732 | 0.82 | NAMPT (0.47) | TSHRFAAHADH1BADH1AADH7 | |
| SCHEMBL24950323 | 0.79 | MEN1 (0.48) | TSHRFAAHMEN1KMT2AEPHX1 | |
| SCHEMBL25591306 | 0.79 | ALDH1A1 (0.42) | TSHRFAAHADH1BADH1AADH7 | |
| SCHEMBL22849696 | 0.79 | KDM4E (0.54) | TSHRFAAHMEN1KMT2ASPR | |
| SCHEMBL10311845 | 0.79 | SPR (0.41) | TSHRFAAHSPRALDH1A1LMNA | |
| SCHEMBL23568563 | 0.79 | KDM4E (0.60) | TSHRFAAHMEN1KMT2ASPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10874743-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874743-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TSHR 3319/4885FAAH 1771/4885ADH1B 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.